Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD/MAD Study of Yiqibuvir (HEC110114) in Healthy Adults
NCT03903081Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of encofosbuvir in hepatitis C (HCV) (10 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse Events. Started Mar 2019; status: completed.
02
Drugs
encofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03903081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903081.